Literature DB >> 21952168

Optimization of hCFTR lung expression in mice using DNA nanoparticles.

Linas Padegimas1, Tomasz H Kowalczyk, Sam Adams, Chris R Gedeon, Sharon M Oette, Karla Dines, Susannah L Hyatt, Ozge Sesenoglu-Laird, Olena Tyr, Robert C Moen, Mark J Cooper.   

Abstract

Efficient and prolonged human cystic fibrosis transmembrane conductance regulator (hCFTR) expression is a major goal for cystic fibrosis (CF) lung therapy. A hCFTR expression plasmid was optimized as a payload for compacted DNA nanoparticles formulated with polyethylene glycol (PEG)-substituted 30-mer lysine peptides. A codon-optimized and CpG-reduced hCFTR synthetic gene (CO-CFTR) was placed in a polyubiquitin C expression plasmid. Compared to hCFTR complementary DNA (cDNA), CO-CFTR produced a ninefold increased level of hCFTR protein in transfected HEK293 cells and, when compacted as DNA nanoparticles, produced a similar improvement in lung mRNA expression in Balb/c and fatty acid binding protein promoter (FABP) CF mice, although expression duration was transient. Various vector modifications were tested to extend duration of CO-CFTR expression. A novel prolonged expression (PE) element derived from the bovine growth hormone (BGH) gene 3' flanking sequence produced prolonged expression of CO-CFTR mRNA at biologically relevant levels. A time course study in the mouse lung revealed that CO-CFTR mRNA did not change significantly, with CO-CFTR/mCFTR geometric mean ratios of 94% on day 2, 71% on day 14, 53% on day 30, and 14% on day 59. Prolonged CO-CFTR expression is dependent on the orientation of the PE element and its transcription, is not specific to the UbC promoter, and is less dependent on other vector backbone elements.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21952168      PMCID: PMC3255587          DOI: 10.1038/mt.2011.196

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  20 in total

1.  Nanoparticles of compacted DNA transfect postmitotic cells.

Authors:  Ge Liu; DeShan Li; Murali K Pasumarthy; Tomasz H Kowalczyk; Christopher R Gedeon; Susannah L Hyatt; Jennifer M Payne; Timothy J Miller; Peter Brunovskis; Tamara L Fink; Osman Muhammad; Robert C Moen; Richard W Hanson; Mark J Cooper
Journal:  J Biol Chem       Date:  2003-06-14       Impact factor: 5.157

2.  Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution.

Authors:  Michael W Konstan; Pamela B Davis; Jeffrey S Wagener; Kathleen A Hilliard; Robert C Stern; Laura J H Milgram; Tomasz H Kowalczyk; Susannah L Hyatt; Tamara L Fink; Christopher R Gedeon; Sharon M Oette; Jennifer M Payne; Osman Muhammad; Assem G Ziady; Robert C Moen; Mark J Cooper
Journal:  Hum Gene Ther       Date:  2004-12       Impact factor: 5.695

Review 3.  CpG methylation, chromatin structure and gene silencing-a three-way connection.

Authors:  A Razin
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

4.  Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus.

Authors:  B G Harvey; P L Leopold; N R Hackett; T M Grasso; P M Williams; A L Tucker; R J Kaner; B Ferris; I Gonda; T D Sweeney; R Ramalingam; I Kovesdi; S Shak; R G Crystal
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

5.  A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction.

Authors:  J R Dorin; R Farley; S Webb; S N Smith; E Farini; S J Delaney; B J Wainwright; E W Alton; D J Porteous
Journal:  Gene Ther       Date:  1996-09       Impact factor: 5.250

6.  Cell-specific posttranscriptional regulation of CFTR gene expression via influence of MAPK cascades on 3'UTR part of transcripts.

Authors:  Maryvonne Baudouin-Legros; Alexandre Hinzpeter; Amandine Jaulmes; Franck Brouillard; Bruno Costes; Pascale Fanen; Aleksander Edelman
Journal:  Am J Physiol Cell Physiol       Date:  2005-06-08       Impact factor: 4.249

7.  DNA nanoparticles: detection of long-term transgene activity in brain using bioluminescence imaging.

Authors:  David M Yurek; Anita M Fletcher; Matthew McShane; Tomasz H Kowalczyk; Linas Padegimas; Marcy R Weatherspoon; Michael D Kaytor; Mark J Cooper; Assem G Ziady
Journal:  Mol Imaging       Date:  2011-04-27       Impact factor: 4.488

8.  Transfection of airway epithelium by stable PEGylated poly-L-lysine DNA nanoparticles in vivo.

Authors:  Assem-Galal Ziady; Christopher R Gedeon; Timothy Miller; William Quan; Jennifer M Payne; Susannah L Hyatt; Tamara L Fink; Osman Muhammad; Sharon Oette; Tomasz Kowalczyk; Murali K Pasumarthy; Robert C Moen; Mark J Cooper; Pamela B Davis
Journal:  Mol Ther       Date:  2003-12       Impact factor: 11.454

9.  Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung.

Authors:  Assem-Galal Ziady; Christopher R Gedeon; Osman Muhammad; Virginia Stillwell; Sharon M Oette; Tamara L Fink; Will Quan; Tomasz H Kowalczyk; Susannah L Hyatt; Jennifer Payne; Angela Peischl; J E Seng; Robert C Moen; Mark J Cooper; Pamela B Davis
Journal:  Mol Ther       Date:  2003-12       Impact factor: 11.454

10.  Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis.

Authors:  L G Johnson; J C Olsen; B Sarkadi; K L Moore; R Swanstrom; R C Boucher
Journal:  Nat Genet       Date:  1992-09       Impact factor: 38.330

View more
  11 in total

1.  Shikonin inhibits TNF-α production through suppressing PKC-NF-κB-dependent decrease of IL-10 in rheumatoid arthritis-like cell model.

Authors:  Wen-Xiao Sun; Yan Liu; Wei Zhou; He-Wei Li; Jian Yang; Zhen-Bing Chen
Journal:  J Nat Med       Date:  2016-12-09       Impact factor: 2.343

2.  S/MAR-containing DNA nanoparticles promote persistent RPE gene expression and improvement in RPE65-associated LCA.

Authors:  Adarsha Koirala; Rasha S Makkia; Shannon M Conley; Mark J Cooper; Muna I Naash
Journal:  Hum Mol Genet       Date:  2013-01-18       Impact factor: 6.150

3.  Persistence of non-viral vector mediated RPE65 expression: case for viability as a gene transfer therapy for RPE-based diseases.

Authors:  Adarsha Koirala; Shannon M Conley; Rasha Makkia; Zhao Liu; Mark J Cooper; Janet R Sparrow; Muna I Naash
Journal:  J Control Release       Date:  2013-09-11       Impact factor: 9.776

Review 4.  Gene therapy for retinal disease.

Authors:  Michelle E McClements; Robert E MacLaren
Journal:  Transl Res       Date:  2013-01-08       Impact factor: 7.012

5.  Comparative analysis of DNA nanoparticles and AAVs for ocular gene delivery.

Authors:  Zongchao Han; Shannon M Conley; Rasha Makkia; Junjing Guo; Mark J Cooper; Muna I Naash
Journal:  PLoS One       Date:  2012-12-18       Impact factor: 3.240

6.  Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy.

Authors:  Brandon K Sack; Sherin Merchant; David M Markusic; Amit C Nathwani; Andrew M Davidoff; Barry J Byrne; Roland W Herzog
Journal:  PLoS One       Date:  2012-05-24       Impact factor: 3.240

7.  DNA nanoparticles are safe and nontoxic in non-human primate eyes.

Authors:  Ryan A Kelley; Shannon M Conley; Rasha Makkia; Jamie N Watson; Zongchao Han; Mark J Cooper; Muna I Naash
Journal:  Int J Nanomedicine       Date:  2018-03-08

8.  Low-Dose Gene Therapy for Murine PKU Using Episomal Naked DNA Vectors Expressing PAH from Its Endogenous Liver Promoter.

Authors:  Hiu Man Grisch-Chan; Andrea Schlegel; Tanja Scherer; Gabriella Allegri; Raphael Heidelberger; Panagiota Tsikrika; Marco Schmeer; Martin Schleef; Cary O Harding; Johannes Häberle; Beat Thöny
Journal:  Mol Ther Nucleic Acids       Date:  2017-04-20

9.  Suprachoroidally Delivered DNA Nanoparticles Transfect Retina and Retinal Pigment Epithelium/Choroid in Rabbits.

Authors:  Viral S Kansara; Mark Cooper; Ozge Sesenoglu-Laird; Leroy Muya; Robert Moen; Thomas A Ciulla
Journal:  Transl Vis Sci Technol       Date:  2020-12-15       Impact factor: 3.283

Review 10.  Vector Design for Improved DNA Vaccine Efficacy, Safety and Production.

Authors:  James A Williams
Journal:  Vaccines (Basel)       Date:  2013-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.